Sierra Believes It Can Do Better Than Gilead With JAK Inhibitor Momelotinib
Executive Summary
With many on the executive team who worked on the drug previously, Sierra thinks the stalled Phase III compound could be differentiated from Jakafi and others in the myelofibrosis space based on anemia benefit.
You may also be interested in...
Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
In NASH, Gilead Swung For The Fences And Struck Out Again
Gilead took a risky approach with selonsertib in NASH, pursuing a tough liver fibrosis benefit and failing, continuing a trend of disappointments outside of its antiviral franchises. Analysts don’t expect the second Phase III study in less-sick patients to succeed either.
Deal Watch: Emergent Strikes Again, Acquiring Adapt And Its Opioid Overdose Drug For $635m
Following its purchase of PaxVax earlier this month, Emergent is taking on Narcan nasal spray for opioid overdose as part of its acquisition of Adapt. Also-busy Evotec teams up with Centogene in rare genetic disease and Novo in diabetes/obesity.
Need a specific report? 1000+ reports available
Buy Reports